Date	e:2022/8/2	9	
You	r Name: Yi-Mir	ng Ma	
Man	nuscript Title: Efficacy a	and optimal combination t	iming of chemotherapy combined with PD-1 inhibitor in
adva	anced cervical cancer: a mul	ticenter retrospective coh	ort study
Man	nuscript number (if known):		
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	of planning of the work
1	All support for the present	X None	in planning of the work
1	All support for the present manuscript (e.g., funding,	xnone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		· · · ·	126
2	Grants or contracts from	Time frame: pas X None	t 36 months
_	any entity (if not indicated	^_NOTIE	
	in item #1 above).		
3	Royalties or licenses	XNone	

4

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
	incettings array or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Dia-	see cummanize the chare se	nflict of intorest in the fell	owing hove
riea	ase summarize the above co	milet of interest in the foll	owing nox:
N	lone.		

Date	e:2022/8/2	.9	
	r Name: Shu-X		
adva	nuscript Title: Efficacy a anced cervical cancer: a mul nuscript number (if known):	lticenter retrospective co	timing of chemotherapy combined with PD-1 inhibitor in phort study
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mo affected by the content ecessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	following questions apply touscript only.	o the author's relationsh	nips/activities/interests as they relate to the current
to tl		nsion, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the init	tial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	to time initial time item.		
		Time frame: pa	ast 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	X None			
	testimony				
	,				
7	Support for attending	X None			
_	meetings and/or travel				
	, , , , , , , , , , , , , , , , , , , ,				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
'\	lone.				

Date	e:2022/8/2	9	
You	r Name: Ming-	Chuan Zhang	
Mar	nuscript Title: Efficacy a	and optimal combination t	iming of chemotherapy combined with PD-1 inhibitor in
adv	anced cervical cancer: a mul	lticenter retrospective coh	ort study
Mar	nuscript number (if known):		
rela part to t	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the current
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	= = = = = = = = = = = = = = = = = = =	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	ito time illine for tims recini		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Dlos	ase summarize the above co	nflict of interest in the following	owing hov:
FIE	ise summanize the above to	milet of interest in the follo	OWING NOV.
	lono		
N	None.		

Date	e:2022/8/2	.9		
You	r Name: Hui-Yi	ing Zhang		
		-		ming of chemotherapy combined with PD-1 inhibitor in
	anced cervical cancer: a mul	-	ive coho	ort study
Mar	nuscript number (if known):			
In th	ne interest of transparency	we ask you to discl	ose all r	elationships/activities/interests listed below that are
rela	ted to the content of your n	nanuscript. "Relate	d" mear	ns any relation with for-profit or not-for-profit third
•	•	-		the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	tionship/activity/interest, it	-		
	donompy decivity, meerest, it	e is preferable that	you uo s	
	following questions apply touscript only.	o the author's relat	ionships	s/activities/interests as they relate to the <u>current</u>
to tl	ne epidemiology of hyperte	nsion, you should d	eclare a	efined broadly. For example, if your manuscript pertains III relationships with manufacturers of antihypertensive
med	lication, even if that medica	ation is not mention	ed in th	e manuscript.
1 !#	#4 h			in this manuscript with sutting limit. For all other its man
	em #1 below, report all sup time frame for disclosure is	=	-	in this manuscript without time limit. For all other items
uie	tille frame for disclosure is	the past 30 months	.	
		Name all entities w		Specifications/Comments
		whom you have thi		(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	cate	institution)
		needed)		
			he initial	planning of the work
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.) No time limit for this item.			
	No time minit for this item.			
		Time fran	ne: past	36 months
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
_			
١	lone.		

Date	e:2022/8/2	.9	
You	r Name: Jun-Jia	ao Gu	
Mar	nuscript Title: Efficacy a	and optimal combination t	iming of chemotherapy combined with PD-1 inhibitor in
adv	anced cervical cancer: a mul	ticenter retrospective coh	ort study
Mar	uscript number (if known):		
rela part to ti rela	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. it is preferable that you do	
		o tne author's relationship	os/activities/interests as they relate to the <u>current</u>
mar	uscript only.		
to tl med In it	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare ition is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other item
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Ti 6	26 months
2	Grants or contracts from	Time frame: pass	t 56 months
_	any entity (if not indicated	^NOTIE	
	in item #1 above).		
3	Royalties or licenses	X None	
	,		

Consulting fees

	1				
5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
IN	lone.				

Date	e:2022/8/2	.9	
You	r Name: Pan-P	an Zhao	
Mar	nuscript Title: Efficacy a	and optimal combination	timing of chemotherapy combined with PD-1 inhibitor in
	anced cervical cancer: a mul		hort study
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.
	following questions apply to uscript only.	o the author's relationshi	ips/activities/interests as they relate to the current
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	<u> </u>	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		-
		Time frame: pa	st 36 months
2	Crants or contracts from	X None	
	Grants or contracts from		
	any entity (if not indicated		
	any entity (if not indicated in item #1 above).		
3	any entity (if not indicated	XNone	
3	any entity (if not indicated in item #1 above).		

Consulting fees

	1				
5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
IN	lone.				

Date	e:2022/8/2	.9			
You	r Name: Hong	Ge			
Mar	nuscript Title: Efficacy a	and optimal combination	timing of chemotherapy combined with PD-1 inhibitor in		
adva	anced cervical cancer: a mul	lticenter retrospective co	phort study		
Mar	nuscript number (if known):				
rela part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" me affected by the content ecessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a o so.		
	following questions apply t uscript only.	o the author's relationsh	sips/activities/interests as they relate to the current		
to th		nsion, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.		
	em #1 below, report all sup time frame for disclosure is	=	ed in this manuscript without time limit. For all other items,		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone			
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: pa	ast 36 months		
2	Grants or contracts from	XNone			
	any entity (if not indicated				
3	in item #1 above).	V None			
5	Royalties or licenses	XNone			

Consulting fees

			T	
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Please summarize the above conflict of interest in the following box: None.				